ADA and cancer: In a similar assessment, Davda and colleagues reviewed the incidence of ADA and NAb across multiple, approved, anti-cancer antibody-based immunomodulatory agents and found that the data is suggestive of a higher likelihood of immunogenicity to antibodies with T cell or APC targets compared to B cell targets (11).